A Phase 2 interventional study of Lifitegrast and Placebo in Dry Eye, sponsored by Shire. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-09.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.
Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 2, and was the 1st registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Toyos Clinic · Sites in United States
Ages 18+
Pittsburgh Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 38 across the 22 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 5 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing lifitegrast in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of three different concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of dry eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Ophthalmic Solution
Drug: Placebo
Lifitegrast
Drug: Lifitegrast
Lifitegrast
Drug: Lifitegrast
Lifitegrast
Drug: Lifitegrast
Ophthalmic Solution
Also known as: SAR 1118
Ophthalmic Solution
Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84
Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.
Time frame: Day 84
Inferior Corneal Staining Score Change From Baseline (CFB) to Day 84
Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.
Time frame: Baseline (Day 0) and Day 84
| Milestone | Lifitegrast 0.1% | Lifitegrast 1.0% | Lifitegrast 5.0% | Placebo |
|---|---|---|---|---|
| Started | 57 | 57 | 58 | 58 |
| Completed | 54 | 51 | 48 | 48 |
| Not completed | 3 | 6 | 10 | 10 |
Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.
| units on a scale | Lifitegrast 0.1% | Lifitegrast 1.0% | Lifitegrast 5.0% | Placebo |
|---|---|---|---|---|
| Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84 | 2.03 ± 0.868 | 1.92 ± 0.768 | 1.83 ± 0.680 | 2.05 ± 0.715 |
Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.
| units on a scale | Lifitegrast 0.1% | Lifitegrast 1.0% | Lifitegrast 5.0% | Placebo |
|---|---|---|---|---|
| Pre-CAE: Baseline | 1.78 ± 0.473 | 1.82 ± 0.508 | 1.77 ± 0.515 | 1.65 ± 0.513 |
| Pre-CAE: CFB to Day 84 | 0.25 ± 0.841 | 0.10 ± 0.735 | 0.05 ± 0.773 | 0.40 ± 0.802 |
| Post-CAE: Baseline | 3.18 ± 0.417 | 3.28 ± 0.610 | 3.16 ± 0.523 | 3.04 ± 0.602 |
| Post-CAE: Day 84 | 2.86 ± 0.962 | 2.88 ± 0.860 | 2.90 ± 0.918 | 2.62 ± 0.855 |
Collected over From the first dose of study drug until the end of follow-up visit, up to Day 86. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lifitegrast 0.1% | — | 2/57 (3.5%) | 20/57 (35.1%) |
| Lifitegrast 1.0% | — | 1/57 (1.8%) | 13/57 (22.8%) |
| Lifitegrast 5.0% | — | 0/58 (0%) | 40/58 (69%) |
| Placebo | — | 1/58 (1.7%) | 11/58 (19%) |
| Event | Lifitegrast 0.1% | Lifitegrast 1.0% | Lifitegrast 5.0% | Placebo |
|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/57 | 1/57 | 0/58 | 0/58 |
| Hip fractureInjury, poisoning and procedural complications | 1/57 | 0/57 | 0/58 | 0/58 |
| Oxygen saturation decreasedInvestigations | 1/57 | 0/57 | 0/58 | 0/58 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/57 | 0/57 | 0/58 | 1/58 |
| Event | Lifitegrast 0.1% | Lifitegrast 1.0% | Lifitegrast 5.0% | Placebo |
|---|---|---|---|---|
| Instillation site irritationGeneral disorders | 7/57 | 5/57 | 20/58 | 6/58 |
| Instillation site painGeneral disorders | 6/57 | 3/57 | 20/58 | 3/58 |
| Instillation site reactionGeneral disorders | 0/57 | 1/57 | 8/58 | 0/58 |
| DysgeusiaNervous system disorders | 1/57 | 2/57 | 7/58 | 0/58 |
| Visual acuity reducedEye disorders | 6/57 | 2/57 | 1/58 | 3/58 |
| Conjunctival haemorrhageEye disorders | 0/57 | 2/57 | 3/58 | 0/58 |
Intent-to-treat (ITT) set included all randomized participants.
| Age, Continuous(years) | Lifitegrast 0.1% | Lifitegrast 1.0% | Lifitegrast 5.0% | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 63.14 ± 13.100 | 63.63 ± 11.883 | 62.26 ± 12.220 | 60.38 ± 12.930 | 62.34 ± 12.523 |
| Sex: Female, Male(Participants) | Lifitegrast 0.1% | Lifitegrast 1.0% | Lifitegrast 5.0% | Placebo | Total |
|---|---|---|---|---|---|
| Female | 47 | 40 | 47 | 45 | 179 |
| Male | 10 | 17 | 11 | 13 | 51 |
Ran from Aug 2009 to primary completion in Feb 2010, 6 months.
Results were first posted in Mar 2017, 7 years after primary completion. A results delay was requested in Jul 2013.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 6 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lifitegrast